Cross-Sector entity
Bachem is most often covered alongside Codexis, which appears in 2 of these 3 stories. Across a 14-day span, the pace is roughly 1.5 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category.
3 verified stories tracked
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Bachem is most often covered alongside Codexis, which appears in 2 of these 3 stories. Across a 14-day span, the pace is roughly 1.5 stories per week. The busiest single day carried 2. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. This profile follows 3 Cross-Sector stories mentioning Bachem across the period from March 11, 2026 to March 24, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bachem. Shared-story counts are live from our verified record — not editorial picks.
Analyst Sentiment Review
Major firms maintain ratings, citing steady execution of the strategic pivot.
Analyst Upgrade
Wall Street Zen upgrades CDXS rating following financial results.
2026 Guidance Issued
Management outlines $72M-$76M revenue target driven by ECO Synthesis.
Q4 2025 Earnings Release
Codexis reports significant beats on both top and bottom lines.
TD Cowen Conference
CEO touts ECO Synthesis push and 2026 inflection targets.
Codexis reported a significant Q4 2025 earnings beat, driven by its ECO Synthesis platform and expanding CDMO partnerships. Despite a raised 2026 revenue outlook and a surprise GAAP profit, analyst sentiment remains largely unchanged as the market awaits further commercial validation of its RNA manufacturing technology.
Codexis (CDXS) has maintained steady analyst sentiment following a strong Q4 2025 performance that exceeded revenue and earnings expectations. The company’s strategic pivot toward its ECO Synthesis platform for RNA manufacturing is gaining commercial traction, supported by a 2026 revenue target of $72M–$76M.
Source: finance.yahoo.com · insidermonkey.com
Bachem (BCHMF) is set to release its quarterly earnings this Thursday, with investors closely monitoring the Swiss CDMO's ability to scale production for the booming GLP-1 market. As a critical supplier of peptides and oligonucleotides, Bachem's financial performance and capacity expansion updates will serve as a bellwether for the broader weight-loss drug supply chain.
Source: themarketsdaily.com · tickerreport.com
